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Abstract
 Background—Expert recommendations do not recommend using Pap or human 
papillomavirus (HPV) test results to determine whether unvaccinated females should receive HPV 
vaccine, nor do they recommend using vaccine receipt to inform cervical cancer screening 
practices. This study characterizes physicians’ HPV vaccine recommendations and practices in the 
context of HPV and Pap testing.
 Methods—We surveyed family physicians and obstetrician-gynecologists randomly selected 
from the American Medical Association Masterfile in 2011 (n = 574). Physicians used a 5-point 
scale (never to always) to report the frequency of (1) using HPV testing results to decide whether 
to recommend HPV vaccine, and (2) recommending HPV vaccination to females (≤26 years) who 
had an abnormal Pap test. Physicians also reported (3) intention to change Pap screening 
frequency for vaccinated females.
 Results—Across both specialties, 80% correctly reported rarely or never using HPV testing 
results to guide vaccine recommendations; 66% often or always recommended vaccination to 
patients with an abnormal Pap result; and 77% did not plan to change Pap screening frequency for 
vaccinated females. About 41% reported recommendation-consistent practices with all three 
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measures. In multivariable analysis, obstetrician-gynecologist specialty and private practice type 
were associated with higher average overall adherence to recommendations.
 Conclusions—Contrary to expert recommendations, a considerable minority of physicians 
reported recommending HPV vaccination based on HPV and Pap test results. If these clinical 
practices persist, many young adult women will not realize the benefits of HPV vaccination. 
Additional efforts are needed to ensure all young women are screened and vaccinated 
appropriately.
Short Summary
In a national study, a considerable minority of family physicians and obstetrician-gynecologists 
reported using HPV and Pap test results to guide their HPV vaccination recommendations for 
females ages ≤26 years.
Keywords
cervical cancer; females; human papillomavirus vaccines; Pap test; physicians
 Introduction
In the United States, the Advisory Committee on Immunization Practices (ACIP) 
recommends routine human papillomavirus (HPV) vaccination for females ages 11–12 years 
and catch-up vaccination up to age 26, regardless of prior HPV exposure.1 ACIP does not 
recommend using prevaccination assessments to determine the appropriateness of HPV 
vaccination;2,3 thus, physicians should not use Papanicolaou (Pap) or HPV test results to 
determine whether to offer HPV vaccination, nor should they use vaccine receipt to inform 
cervical cancer screening practices. Yet, available studies suggest many providers who 
deliver cervical cancer screening services for women report intended4 or actual5,6 practices 
inconsistent with ACIP recommendations, including failing to recommend HPV vaccine for 
females with a history of an abnormal Pap test or positive HPV test.
As cervical cancer screening and HPV vaccine guidelines evolve, it is important to 
understand physicians’ current practices and adherence to ACIP recommendations when 
making HPV vaccine recommendations to young adult female patients. This study 
characterizes physicians’ HPV vaccine recommendations and practices in the context of 
HPV and Pap testing, and explores differences in adherence to expert recommendations by 
personal and practice characteristics.
 Materials and Methods
 Sample and recruitment
The sample and recruitment methods were previously described.7,8 Briefly, we mailed 
surveys to nationally representative samples of family physicians (FPs; n = 746), 
pediatricians (n = 473), and obstetrician-gynecologists (OBGYNs; n = 322) randomly 
selected from the American Medical Association Physician Masterfile in 2011. We received 
completed surveys from 928 physicians, including 406 FPs, 322 pediatricians, and 200 
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OBGYNs. After excluding undeliverable surveys (n = 43) and ineligible respondents (n = 
15) from the denominator, the overall response rate was 62.6%. Specialty-specific response 
rates were 56.7% for FPs, 70.2% for pediatricians, and 64.9% for OBGYNs.
Based on study variables of interest, we excluded pediatricians from the current study 
because the majority reported that two of the three outcome variables were not applicable to 
them. We also excluded physicians who reported they do not recommend HPV vaccine (n = 
23). Early in the survey, these physicians were instructed to skip several questions pertaining 
to HPV vaccine recommendations, including two of the three outcome variables for this 
analysis. Finally, we excluded physicians with missing data for all three outcomes (n = 9). 
The final analytic sample size of 574 physicians was comprised of 383 FPs and 191 
OBGYNs. The University of South Florida Institutional Review Board granted a waiver of 
documentation of informed consent for this study.
 Instrument
Three survey items assessed physicians’ HPV vaccine recommendations and practices in the 
context of HPV and Pap testing. These practice questions were considered indicators of 
following ACIP recommendations, and an ACIP recommendation-consistent response was 
deemed correct. The first item asked: “How often do you use HPV testing results to make a 
decision about whether to recommend the HPV vaccine to your female patients?” (Practice 
Question 1). Physicians responded using a 5-point scale ranging from never to always. Per 
ACIP recommendations, and accounting for any rare, yet valid exceptions to the 
recommendations, a rarely or never response to this item was considered correct. For the 
second item, we asked physicians: “Among your female patients age 26 years and younger, 
how often do you recommend HPV vaccination if they had an abnormal Pap test?” (Practice 
Question 2). Physicians responded using a similar scale as the first item, plus an additional 
option: N/A – I don’t perform Pap tests. Physicians who selected this response or had 
missing data for this item were excluded from analyses for this outcome; otherwise, an often 
or always response was considered correct. For the third item, we asked physicians: “Do you 
plan to change the frequency with which you provide Pap test screening to females who 
have received the HPV vaccine?” (yes, no, don’t know, N/A – I don’t perform Pap tests; 
correct response = no) (Practice Question 3). Similar to the previous item, physicians who 
indicated the item was not applicable or had missing data were excluded from analyses for 
this outcome. In addition to examining each practice question independently, we assessed 
the extent to which physicians’ practices are aligned with ACIP recommendations by 
summing correct responses to the three practice questions to create an overall practice 
indicator (range: 0–3). We examined participants’ demographic and practice characteristics 
as correlates of each practice question and of the practice indicator.
 Data analysis
Data were summarized with descriptive statistics using SAS version 9.4 (SAS Institute Inc., 
Cary, NC). We examined the association between each practice question and participants’ 
demographic and practice characteristics using Fisher’s Exact test. Variables that were 
statistically significant in these bivariate analyses were included in a multivariable logistic 
regression model. We also examined the association between the practice indicator and 
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demographic and practice characteristics using Wilcoxon Rank Test for independent 
variables with two levels, or Kruskal-Wallis test for variables with more than two levels. 
Variables that were statistically significant in these analyses were included in a regression 
model. Analyses were completed in 2015.
 Results
Over half (56%) of the 574 physicians were male and 41% were ages 50–65 years (Table 1). 
Most physicians were White/Caucasian (74%) and not Hispanic or Latino (90%). About 
two-thirds (67%) of physicians were FPs. The highest percentage of physicians reported 
their practice had 2–15 physicians (64%), was single-specialty (74%), was a private practice 
(71%), was located in a suburban area (51%), and was in the South (33%). Regarding patient 
characteristics, 49% indicated over half of their patients were privately insured and 74% 
indicated the majority of their patients were non-Hispanic White.
Given that the survey was anonymous, we were unable to determine whether survey 
responders and non-responders were similar on demographic and practice characteristics. 
However, it was possible to compare responding FPs and OBGYNs to national data on 
physicians9 regarding characteristics including sex, age, and region. We found no 
statistically significant difference in sex between national data and responding FPs (p = .32) 
or OBGYNs (p = .62). Regarding age, there was a significant difference between national 
data and responding FPs (p < .01), but not for OBGYNs (p = .30). For region, there was no 
significant difference between national data and responding FPs (p = .11) or OBGYNs (p = .
13).
 Individual practice questions
 Using HPV test results to guide vaccine recommendations (Practice 
Question 1)—Across the sample, 80% (458/572) correctly reported rarely or never using 
HPV testing results to guide HPV vaccine recommendations. In bivariate analyses, physician 
race, number of physicians and specialties in the practice, and patient race were statistically 
significantly associated with a correct response to the practice question (Table 1). In 
multivariable analysis, physician race and number of physicians in the practice retained 
statistical significance (Table 2). Compared to physicians who were White/Caucasian, 
physicians who reported they were of another race had lower odds of a correct response 
(odds ratio [OR], 0.48; 95% confidence interval [CI], 0.29–0.78). Physicians whose practice 
consisted of 16 or more physicians had higher odds of a correct response compared to 
physicians practicing alone (OR, 3.30; 95% CI, 1.02–10.75).
 HPV vaccine recommendation in light of an abnormal Pap test result 
(Practice Question 2)—About 66% (357/542) of physicians reported they often or 
always recommended HPV vaccination to patients with an abnormal Pap test result. Clinical 
specialty was the only variable significantly associated with a correct response (Table 1). 
OBGYNs had higher odds of a correct response compared to FPs (OR, 1.53; 95% CI, 1.04–
2.25) (Table 2).
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 Plans to change Pap screening frequency for vaccinated females (Practice 
Question 3)—About 77% (413/538) did not plan to change Pap test frequency for 
vaccinated females. Physician age, clinical specialty, and practice type were significantly 
associated with a correct response to this question (Table 1). All three variables retained 
statistical significance in the multivariable model. Physicians ages 50–65 years had lower 
odds of a correct response compared to those ages 30–39 (OR, 0.51; 95% CI, 0.29–0.92). 
Relative to FPs, OBGYNs had higher odds of a correct response (OR, 1.60; 95% CI, 1.01–
2.54). Physicians practicing in a setting other than a private practice office (e.g., urgent care 
clinic, community health center) had lower odds of a correct response compared to those in 
private practice (OR, 0.62; 95% CI, 0.39–0.98).
 Practice indicator
About 41% (236/574) of physicians reported guideline-consistent practices with all three 
indicators. The mean indicator score was 2.14 (standard deviation = 0.85; range = 0–3). Age, 
sex, clinical specialty, practice type, patient payment method, and patient race were 
significantly associated with practice indicator distribution in bivariate analyses (Table 3). In 
the multivariable model, OBGYN clinical specialty and private practice type were associated 
with a higher practice indicator.
 Discussion
Despite ACIP recommendations,2,3 a considerable minority of physicians reported 
recommending HPV vaccination based on HPV (20%) and Pap test (34%) results. Although 
HPV vaccines are preventative, and do not reduce disease burden in women already infected 
with vaccine-type virus, neither Pap tests nor clinically available HPV tests used in women 
under age 26 generally specify the type of HPV infection, and thus withholding vaccination 
from women with abnormal Pap or HPV results is not recommended.
Our finding that 80% of physicians rarely or never use HPV testing results to guide HPV 
vaccine recommendations is similar to previous research documenting that 73–79% of 
providers sometimes to always recommend HPV vaccine to females with a positive HPV 
test.5,6 We also found that about 66% of physicians reported they often or always 
recommended HPV vaccination to patients with an abnormal Pap test result, compared to 
79–85% who sometimes to always did so in previous research.5,6 Differences in analyses 
may have accounted for the lower proportion of physicians adhering to this practice 
recommendation in our study. In our study, we did not consider a sometimes response to 
reflect sufficiently consistent adherence to practice guidelines. Variation between the current 
study and previous research also could be due to differences in the provider population 
studied, with previous research including nurse practitioners, certified nurse midwives, and 
physician assistants in addition to physicians.6
Aligned with published clinical practice guidelines,10–12 many (77%) physicians in our 
study did not plan to change Pap frequency for vaccinated females. However, fewer 
physicians (66%) reported recommending HPV vaccination to patients with an abnormal 
Pap test result. ACIP guidelines,1 which are endorsed by the American Academy of 
Pediatrics (AAP),13 American Academy of Family Physicians (AAFP),14 and American 
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College of Obstetricians and Gynecologists (ACOG),15 recommend universal vaccination 
for females through age 26. Our previous work demonstrates physicians look to their 
professional organizations for guidance on HPV vaccination.16 Although the AAP, AAFP, 
and ACOG endorse the ACIP’s recommendations for universal HPV vaccination, data from 
the current study suggest gaps in adherence to these recommendations. It is possible that 
some physicians use an individualized approach suggested by the American Cancer Society 
(ACS) recommendations, which state there are insufficient data to recommend for or against 
universal vaccination of females ages 19–26.17 For this age group, ACS recommendations 
advocate that the decision to vaccinate be based on an informed discussion between a 
woman and her provider about the benefits of HPV vaccination in light of her risk of 
previous HPV exposure and vaccine cost. The presence of contradictory guidelines, such as 
the ACIP and ACS recommendations seen here, has been cited as a behavioral barrier to 
physicians’ adherence to practice guidelines.18
Further research is needed to understand other knowledge, attitudinal, and behavioral 
factors18 that underlie physicians’ non-adherence to the ACIP recommendations. Aligned 
with the awareness-to-adherence model,19 this research may begin by assessing physicians’ 
awareness of the ACIP recommendations. Lack of familiarity with guidelines18 and lack of 
guideline clarity20 have been cited as barriers to guideline adherence. If non-adherence to 
the ACIP recommendations is related to these barriers, then knowledge-based interventions 
focused on increasing awareness and improving guideline clarity can be valuable. Such 
interventions could take the form of continuing medical education. In the current study, we 
identified several potential targets for research and interventions, such as FP clinical 
specialty and physicians in non-private practice settings.
Although awareness of the guidelines is an important first step, awareness alone is unlikely 
to change practice. Our study highlights gaps in guideline-concordant practices related to 
cervical cancer prevention and screening in the era of HPV vaccine availability, but 
deviations from practice guidelines are not unique to this area. Our findings are consistent 
with research showing primary care physicians’ practices depart from guidelines with 
respect to other preventive services.21–23 Given that guidelines attempt to assimilate the best 
available evidence for disease prevention,24 these findings highlight the need for a greater 
emphasis on guideline-concordant preventive care delivery. Guideline implementation likely 
will require a multifaceted approach24 and computer reminders represent a promising 
component for successful implementation.25 Electronic health record prompts already show 
potential for improving HPV vaccine uptake;26 incorporating reminders about practice 
guidelines may also facilitate improved HPV vaccine recommendations.
ACIP recommendations for HPV vaccination were first published in 20071 and updated in 
20102 and 2014.3 In the context of special situations, including an abnormal Pap test or 
known HPV infection, the original recommendations underscored that vaccination would 
provide protection against HPV types not previously acquired.1 The 2010 recommendations 
included clearer guidance for vaccination in special situations by specifying that the use of 
prevaccination assessments (e.g., Pap testing, HPV antibody tests) to determine the 
appropriateness of vaccination are not recommended.2 The most recent ACIP 
recommendations, published in 2014, continue to recommend against using prevaccination 
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assessments.3 The current study’s data were collected the year following the 2010 
recommendations. Future research should focus on assessing current practices, and our data 
provide an important benchmark to which these data can be compared.
Study strengths include surveying nationally representative samples of physicians and a high 
response rate of 62.6%. Physician survey response rates tend to be modest, averaging 54%27 
and varying according to subject. Together, the representative samples and response rate 
enhance the study’s generalizability to U.S. physicians who are involved in HPV vaccine 
dissemination for young women. In light of its strengths, our study is limited by our inability 
to assess the extent to which physicians may have provided socially desirable responses. The 
anonymity of the survey may have reduced this bias. Also, we did not offer quantitative 
anchors or other indicators in the response options for the practice questions, making it 
challenging to assess how physicians may have interpreted the response options. For 
instance, some physicians may have interpreted the always response option to mean 100% of 
the time with no exceptions, whereas other physicians may interpreted this option less 
rigidly (e.g., accounting for a handful of exceptions). As a result, we also included often 
responses to allow flexibility, but perhaps sacrificed some precision in our estimates. Our 
study also may be subject to non-response bias. Although our survey respondents were 
similar to the national population with regard to sex and region, FPs who responded to our 
survey tended to be in the older age groups compared to national data. Of note, some 
research suggests response bias may be less of a concern for surveys conducted with 
physicians compared to the general population.28
By surveying the physician specialties most likely to be involved in HPV vaccination, we 
were able to better understand the practices of physicians who influence HPV vaccine 
uptake among young adult women in the United States. This study highlighted missed 
clinical opportunities for HPV vaccination based on practices that do not follow ACIP 
recommendations. Future research should clarify the guidelines physicians follow, along 
with their interpretation of those guidelines. As vaccination rates at recommended ages 
increase, fewer women will reach young adulthood unvaccinated. However, until this time, 
appropriate catch-up vaccination of the young adult population is important to prevent HPV-
related diseases and cancers. Broad dissemination of clear guidelines that are harmonized 
across organizations is needed to protect the entire population of young adult women.
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